scholarly journals Lung Cancer with Skin and Breast Metastasis: A Case Report and Literature Review

2015 ◽  
Vol 2015 ◽  
pp. 1-6 ◽  
Author(s):  
Bikash Bhattarai ◽  
Marie Frances Schmidt ◽  
Meenakshi Ghosh ◽  
Abhisekh Sinha Ray ◽  
Saveena Manhas ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Case Report ◽  
Primary Lung Cancer ◽  
Radical Mastectomy ◽  
Left Breast ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Patients At Risk ◽  
Poorly Differentiated ◽  
Unclear Etiology

Lung cancer is one of the most common cancers in America. Frequent sites of metastasis include the Hilar lymph nodes, adrenal glands, liver, brain, and bone. The following case report is of a primary lung cancer with metastases to the breast and skin.Case. A 48-year-old African American male with a past medical history of poorly differentiated left breast cancer status after modified radical mastectomy (MRM), chronic obstructive pulmonary disease, and smoking (20 pack-years) presents to the ER with progressive shortness of breath on exertion, upper back pain, and weight loss for 2 months in duration. On physical examination he is found to have a MRM scar on his left breast and a left periumbilical cutaneous mass. Chest X-ray and chest CT reveal a right upper lobe mass and biopsies from the breast, lung, and the periumbilical mass indicate a poorly differentiated carcinoma of unclear etiology; all tumor markers are negative. The patient is male and a chronic smoker; therefore the diagnosis is made as lung carcinoma with metastases to the breast and skin.Conclusion. A high index of suspicion for cutaneous metastases should be cast when investigating cutaneous pathologies in patients at risk for primary lung malignancy.

scholarly journals Primary lung cancer with metastasis to the ipsilateral breast-a case report

2017 ◽  
Vol 6 (1) ◽  
pp. 334 ◽  
Author(s):  
Abdalla Saad Abdalla Al-Zawi ◽  
Andrzej Ratajczak ◽  
Philip Idaewor ◽  
Mohamed Elamass ◽  
Anita Lazarevska ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Case Report ◽  
Malignant Melanoma ◽  
Rare Case ◽  
Primary Lung Cancer ◽  
Left Breast ◽  
Contralateral Breast ◽  
Ipsilateral Breast ◽  
Breast Lump ◽  
Breast Metastases

The metastasis of extra-mammary malignancy to breast is extremely rare; literature reports the incidence between 0.4-1.3%. Primary sites include the contralateral breast, leukaemia, lymphoma, malignant melanoma, sarcoma, lung, prostate, ovary, colon and the stomach. Here we present a rare case in which lung cancer was found to metastasise to the breast. Initially the patient presented with chest symptoms and a left breast lump was detected clinically. The radiological and histological investigations confirmed the diagnosis of primary lung cancer with breast metastases. Prognosis of such cases is generally poor.

scholarly journals THORACIC EPIDURALANESTHESIA FOR MODIFIED RADICAL MASTECTOMY IN CARCINOMA OF BREAST PATIENT WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE: A CASE REPORT

2020 ◽  
pp. 1-2
Author(s):  
Sakthi Vignesh G
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Case Report ◽  
Pulmonary Disease ◽  
Epidural Anesthesia ◽  
Radical Mastectomy ◽  
Thoracic Epidural Anesthesia ◽  
Chronic Obstructive ◽  
Modified Radical Mastectomy ◽  
Obstructive Pulmonary Disease ◽  
Thoracic Epidural

Modified radical mastectomy, the standard surgical procedure in the management of carcinoma of breast is routinely performed under general anaesthesia. Carcinoma breasts patients are considered to be at high risk for anaesthesia due to high possibility of perioperartive complications and mortality when associated COPD with other co morbidities. Here we present a case report of successful perioperative management of modified radical mastectomy only with thoracic epidural anesthesia in a diagnosed case of carcinoma of breast with COPD, hypertension, type 2 diabetes mellitus . case report: A 58-year-old female, a known case of chronic obstructive pulmonary disease since five years with comorbidites (ASA grade III), presented with carcinoma of breast was scheduled for modified radical resection. Continuous thoracic epidural anesthesia was administered at T4-5 level. Local anesthetic supplementation titrated as per the demands of surgery and postoperative analgesia for 48 hours. chromic obstructive pulmonary disease has been considered as independent risk factor for postoperative morbidity and mortality because of cardiopulmonary complications. but thoracic epidural anesthesia, one of the regional anesthesia techniques, with use of low dose of local anesthetic helps preserving respiratory function. the procedure was well tolerated without cardiopulmonary complications which lead to prompt recovery with additional effect of prolonged postoperative analgesia. conclusion: thoracic epidural anesthesia provided not only hemodynamic, cardiopulmonary stability but also adequate anesthesia, analgesia and satisfaction to patient in postoperative phase. It proved to be an excellent anesthesia technique for modified radical mastectomy in patient with chronic obstructive pulmonary disease.

Proteomic and Glycomic Markers to Differentiate Lung Adenocarcinoma from COPD

2020 ◽  
Vol 27 (20) ◽  
pp. 3302-3313 ◽  
Author(s):  
Miklós Szabó ◽  
László Hajba ◽  
Renáta Kun ◽  
András Guttman ◽  
Eszter Csánky
Keyword(s):  
Lung Cancer ◽  
Chronic Obstructive Pulmonary Disease ◽  
Lung Adenocarcinoma ◽  
Pulmonary Disease ◽  
Primary Lung Cancer ◽  
Molecular Diagnostic ◽  
Chronic Obstructive ◽  
Protein Markers ◽  
Obstructive Pulmonary Disease ◽  
Therapeutic Decisions

Lung adenocarcinoma is one of the leading causes of mortality among cancer patients worldwide and Chronic Obstructive Pulmonary Disease (COPD) is also high in death statistics. In addition, patients with Chronic Obstructive Pulmonary Disease (COPD) have a high risk of developing primary lung cancer. Prevention, risk estimation and a non-invasive diagnostics are essential to decrease COPD and lung cancer mortality. Therefore, better and more accurate molecular diagnostic markers (biomarkers) are needed for the early differential diagnosis of these lung diseases to help clinicians make better therapeutic decisions. This review focuses on recently discovered adenocarcinoma and COPD biomarkers at the proteome and glycome level. In the first part, the protein markers are summarized, while the second part is focused on glycan markers. Their use to differentiate between chronic inflammation (COPD) and malignant (adenocarcinoma) diseases is discussed in detail.

scholarly journals Lung Cancer Screening in Patients with COPD—A Case Report

Medicina ◽  
2019 ◽  
Vol 55 (7) ◽  
pp. 364
Author(s):  
Roxana Amirahmadi ◽  
Avnee J. Kumar ◽  
Mark Cowan ◽  
Janaki Deepak M.B.B.S.
Keyword(s):  
Lung Cancer ◽  
Case Report ◽  
Cancer Screening ◽  
Lung Cancer Screening ◽  
Smoking History ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Increased Risk ◽  
Poor Functional Status ◽  
The Impact

We present two cases demonstrating the nuances that must be considered when determining if a patient could benefit from low dose computed tomography (LDCT) lung cancer screening. Our case report discusses the available literature, where it exists, on lung cancer screening with special attention to the impact of chronic obstructive pulmonary disease (COPD), and poor functional status. Patients with COPD and concurrent smoking history are at higher risk of lung cancer and may therefore benefit from lung cancer screening. However, this population is at increased risk for complications related to biopsies and lobar resections. Appropriate interventions other than surgical resection exist for COPD patients with poor pulmonary reserve. Risks and benefits of lung cancer screening are unique to each patient and require shared decision-making.

scholarly journals Salivary Metabolic Profile of Patients with Lung Cancer, Chronic Obstructive Pulmonary Disease of Varying Severity and Their Comorbidity: A Preliminary Study

Diagnostics ◽  
2020 ◽  
Vol 10 (12) ◽  
pp. 1095
Author(s):  
Lyudmila V. Bel’skaya ◽  
Elena A. Sarf ◽  
Denis V. Solomatin ◽  
Victor K. Kosenok
Keyword(s):  
Lung Cancer ◽  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Biochemical Composition ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Kaplan Meier ◽  
Patients At Risk ◽  
Diagnosis Of Lung Cancer ◽  
Imidazole Compounds

The aim of the work was to study the features of the salivary biochemical composition in the combined pathology of lung cancer and chronic obstructive pulmonary disease (COPD) of varying severity (COPD I, COPD II). The study group included patients with lung cancer (n = 392), non-malignant lung pathologies (n = 168) and healthy volunteers (n = 500). Before treatment, the salivary biochemical composition was determined according to 34 indicators. Survival analysis performed by the Kaplan-Meier method. Biochemical parameters (catalase, imidazole compounds ICs, sialic acids, lactate dehydrogenase (LDH)) that can be used to monitor patients at risk (COPD I) for timely diagnosis of lung cancer are determined. A complex of salivary biochemical indicators with prognostic value in lung cancer was revealed. For patients with lung cancer without COPD, a group of patients with a favorable prognosis can be distinguished with a combination of ICs < 0.478 mmol/L and LDH >1248 U/L (HR = 1.56, 95% CI 0.40–6.07, p = 0.03891). For COPD I, a level of ICs < 0.182 mmol/L are prognostically favorable (HR = 1.74, 95% CI 0.71–4.21, p = 0.07270). For COPD II, combinations of pH < 6.74 and LDH >1006 U/L are prognostically favorable. In general, for patients with lung cancer in combination with COPD I, the prognosis is more favorable than without COPD.

scholarly journals Time-ordered comorbidity correlations identify patients at risk of mis- and overdiagnosis

2021 ◽  
Vol 4 (1) ◽  
Author(s):  
Isabella Friis Jørgensen ◽  
Søren Brunak
Keyword(s):  
Lung Cancer ◽  
At Risk ◽  
Diagnostic Errors ◽  
Lung Function Test ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Copd Patients ◽  
Patients At Risk ◽  
The Individual ◽  
Copd Diagnosis

AbstractDiagnostic errors are common and can lead to harmful treatments. We present a data-driven, generic approach for identifying patients at risk of being mis- or overdiagnosed, here exemplified by chronic obstructive pulmonary disease (COPD). It has been estimated that 5–60% of all COPD cases are misdiagnosed. High-throughput methods are therefore needed in this domain. We have used a national patient registry, which contains hospital diagnoses for 6.9 million patients across the entire Danish population for 21 years and identified statistically significant disease trajectories for COPD patients. Using 284,154 patients diagnosed with COPD, we identified frequent disease trajectories comprising time-ordered comorbidities. Interestingly, as many as 42,459 patients did not present with these time-ordered, common comorbidities. Comparison of the individual disease history for each non-follower to the COPD trajectories, demonstrated that 9597 patients were unusual. Survival analysis showed that this group died significantly earlier than COPD patients following a trajectory. Out of the 9597 patients, we identified one subgroup comprising 2185 patients at risk of misdiagnosed COPD without the typical events of COPD patients. In all, 10% of these patients were diagnosed with lung cancer, and it seems likely that they are underdiagnosed for lung cancer as their laboratory test values and survival pattern are similar to such patients. Furthermore, only 4% had a lung function test to confirm the COPD diagnosis. Another subgroup with 2368 patients were found to be at risk of “classically” overdiagnosed COPD that survive >5.5 years after the COPD diagnosis, but without the typical complications of COPD.

Sign in / Sign up

Export Citation Format

Share Document